IC
ARQT icon

IEQ Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

IEQ Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,555
Closed -$568K – 1897
2025
Q4 		$568K Buy
19,555
+2,015
+11% +$51.6K ﹤0.01% 1273
2025
Q3 		$331K Buy
17,540
+615
+4% +$9.7K ﹤0.01% 1477
2025
Q2 		$237K Sell
16,925
-5,157
-23% -$72.3K ﹤0.01% 1524
2025
Q1 		$345K Buy
+22,082
New +$311K ﹤0.01% 1133

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IEQ Capital's ARQT Position: Q1 2026 in Review

IEQ Capital sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 19,555 shares — an estimated $568K sold.

IEQ Capital first reported a position in ARQT in Q1 2025 and held it in 4 quarters. The position peaked at $568K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • IEQ Capital reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • IEQ Capital sold 19,555 Arcutis Biotherapeutics shares in Q1 2026, an estimated $568K.
  • IEQ Capital first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • IEQ Capital's Arcutis Biotherapeutics position peaked at $568K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.